Singapore: The Health Sciences Authority (HSA) stated on Wednesday (November 17) that the Chinese medicine Lianhua Qingwen is not approved for the treatment of COVID-19 symptoms, adding that such declarations are not allowed.
In a consultation, HSA stated that it is aware of the spread in social media and Telegram chat groups that Lianhua Qingwen products can be used to prevent or treat COVID-19.
“Some Lianhua Qingwen products are listed as proprietary Chinese medicines in Singapore for the relief of cold and flu symptoms. HSA has approved them based on the recorded use of the ingredients present in the products,” the authorities said.
“So far, there is no scientific evidence from randomized clinical trials to show that any herbal products, including Lianhua Qingwen products, can be used to prevent or treat COVID-19.”
HSA stated that all herbal products used to treat the common cold and flu can only be used to treat symptoms such as headache, runny or stuffy nose, sore throat and cough.
It added: “We strongly advise the public not to fall prey to unproven claims and not to spread unfounded rumors that herbal products can be used to prevent or treat COVID-19.”
Before Singapore can supply any product that claims to be able to treat COVID-19, it must first be submitted to HSA for scientific evidence evaluation and registration.
Scientific evidence should come from controlled clinical studies, showing that the product is safe and effective against COVID-19.
“Remind distributors and sellers not to make any false or misleading claims that the products they sell can prevent, prevent or treat diseases such as COVID-19,” HSA said.
Such crimes can be punishable by up to two years in prison, a fine of up to S$5,000, or both.
